CytomX Therapeutics, Inc. (CTMX) News
Filter CTMX News Items
CTMX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CTMX News Highlights
- CTMX's 30 day story count now stands at 6.
- Over the past 16 days, the trend for CTMX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about CTMX are ARVN, ATHE and CRSP.
Latest CTMX News From Around the Web
Below are the latest news stories about CYTOMX THERAPEUTICS INC that investors may wish to consider to help them evaluate CTMX as an investment opportunity.
CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 5:15 p.m. PT. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at ww |
Investors in CytomX Therapeutics (NASDAQ:CTMX) have unfortunately lost 90% over the last five yearsCytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders should be happy to see the share price up 26% in the last month... |
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer StudyInterim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients. |
Alterity (ATHE) Up on Preclinical Parkinson's Treatment DataData from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease. |
CRISPR (CRSP) to Focus on Next-Generation CAR T PipelineBased on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates. |
Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis DrugThe FDA accepts Vanda's (VNDA) new drug application ("NDA") for tradipitant for treating the symptoms of gastroparesis. The company's shares rise in after-hours trading. |
AstraZeneca (AZN) to Discontinue Two Studies on LokelmaOwing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma. |
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's WhyAnnovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease. |
AbbVie (ABBV) Posts Encouraging Data From Lung Cancer StudyData from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients. |
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy INDAdaptimmune (ADAP) shares rise as GSK transfers IND for letetresgene autoluecel (lete-cel), which is being developed for treating synovial sarcoma and myxoid/round cell liposarcoma. |